# US 8,278,318 B2 · Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,318 B2
- Document ID: US8278318B2
- Status: Granted
- Kind: B2
- Application number: 12/143,427
- Filed: 2008-06-20
- Published: 2008-12-25
- Granted: 2012-10-02
- Earliest claimed: 2007-06-21
- Assignees: Incyte Corporation
- Inventors: Wenqing Yao; Jincong Zhuo; Colin Zhang
- Web page: https://patentgrep.com/patent/US8278318B2

## CPC

- C07D 471/10: Spiro-condensed systems
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/28: Antiandrogens
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to certain spirocyclic compounds that are inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 (11βHSD1), compositions containing the same, and methods of using the same for the treatment of diabetes, obesity and other diseases.

## Claims

### Claim 1

A compound which is:
5-{3-Fluoro-4-[(5S)-2-(cis-4-hydroxycyclohexyl)-1-oxo-2,7-diazaspiro[4.5]dec-7-yl]phenyl}-N,N-dimethylpyridine-2-carboxamide;
or a pharmaceutically acceptable salt thereof.

### Claim 2

A compound which is:
5-{3-Fluoro-4-[(5S)-2-(cis-4-hydroxycyclohexyl)-1-oxo-2,7-diazaspiro[4.5]dec-7-yl]phenyl}-N-methylpyridine-2-carboxamide;
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1, 2)

A composition comprising a compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

### Claim 4 (depends on 1, 2)

A method of inhibiting activity of 11βHSD1 comprising contacting said 11βHSD1 with a compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1, 2)

A method of inhibiting the conversion of cortisone to cortisol in a cell comprising contacting the cell with a compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1, 2)

A method of inhibiting the production of cortisol in a cell comprising contacting the cell with a compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof.
